ABC | Volume 113, Nº3, September 2019

Review Article Calderado et al. Pulmonary hypertension Arq Bras Cardiol. 2019; 113(3):419-428 This is an open-access article distributed under the terms of the Creative Commons Attribution License 56. Delcroix M, Lang I, Pepke-Zaba J, Jansa P, D’Armini AM, Snijder R, et al. Long-Term Outcome of Patients With Chronic Thromboembolic PulmonaryHypertension:ResultsFroman InternationalProspectiveRegistry. Circulation. 2016;133(9):859-71. 57. Stasch JP, Evgenov OV. Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol. 2013;218:279-313. 58. Ghofrani HA, Simonneau G, D’Armini AM, Fedullo P, Howard LS, Jais X, et al. Macitentanforthetreatmentofinoperablechronicthromboembolicpulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind,placebo-controlledstudy.LancetRespirMed.2017;5(10):785-94. 59. Fukui S, Ogo T, Morita Y, Tsuji A, Tateishi E, Ozaki K, et al. Right ventricular reverse remodelling after balloon pulmonary angioplasty. Eur Respir J. 2014;43(5):1394-402. 60. Fernandes CJ, JardimC, Carvalho LA, Farias AQ, FilhoMT, Souza R. Clinical response to sildenafil in pulmonary hypertension associated with Gaucher disease. J Inherit Metab Dis. 2005;28(4):603-5. 428